-
Je něco špatně v tomto záznamu ?
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
NM. Marina, S. Smeland, SS. Bielack, M. Bernstein, G. Jovic, MD. Krailo, JM. Hook, C. Arndt, H. van den Berg, B. Brennan, B. Brichard, KL. Brown, T. Butterfass-Bahloul, G. Calaminus, HE. Daldrup-Link, M. Eriksson, MC. Gebhardt, H. Gelderblom, J....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- nádory kostí farmakoterapie mortalita MeSH
- osteosarkom farmakoterapie mortalita MeSH
- předškolní dítě MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- senioři MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m(2), doxorubicin 37·5 mg/m(2) per day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m(2) over 4 h. The MAPIE regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m(2)) at 2·8 g/m(2) per day with equidose mesna uroprotection, followed by etoposide 100 mg/m(2) per day over 1 h on days 1-5. The primary outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00134030. FINDINGS: Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6-76·6); 62·3 months (IQR 46·9-77·1) for the MAP group and 61·1 months (IQR 46·5-75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0·98 [95% CI 0·78-1·23]); hazards were non-proportional (p=0·0003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically doxorubicin and cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically doxorubicin). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to methotrexate. INTERPRETATION: EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival. The results define standard of care for this population. New strategies are required to improve outcomes in this setting. FUNDING: UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.
Aarhus University Hospital Aarhus C Denmark
Abt Pädiatrische Radiologie AKK Altonaer Kinderkrankenhaus Hamburg Germany
Bristol Royal Hospital for Children Bristol UK
Center for Cancer and Blood Disorders Connecticut Children's Medical Center Hartford CT USA
Centre for Clinical Trials University Hospital Muenster Muenster Germany
Children's Oncology Group Arcadia CA USA
Clinical Trials Research Unit Institute of Clinical Trials Research University of Leeds Leeds UK
Department of Oncology University College Hospital London UK
Department of Orthopaedics University of British Columbia Vancouver BC Canada
Department of Pathology Boston Children's Hospital Boston MA USA
Department of Pediatric Hemato oncology University Hospital Leuven Leuven Belgium
Department of Pediatric Oncology Klinikum Kassel Kassel Germany
Department of Pediatrics Memorial Sloan Kettering Cancer Center New York NY USA
Department of Pediatrics St Anna Children's Hospital Medical University Vienna Vienna Austria
Department of Pediatrics UT Southwestern and Children's Medical Center Dallas TX USA
Department of Radiology Stanford University and Lucile Packard Children's Hospital Palo Alto CA USA
Department of Surgery Dana Farber Cancer Institute Boston MA USA
Division of Pediatric and Adolescent Medicine Mayo Clinic Rochester MN USA
Division of Pediatric Hematology Oncology The Children's Hospital at Montefiore Bronx NY USA
Division of Pediatrics The University of Texas M D Anderson Cancer Center Houston TX USA
Emma Children Hospital Academic Medical Centre Amsterdam Netherlands
HELIOS Klinikum Berlin Buch Klinik für Interdisziplinäre Onkologie Berlin Germany
HELIOS Klinikum Emil von Behring GmbH Orthopädische Pathologie Berlin Germany
Institute for Clinical Medicine University of Oslo Norway
Institute of Biostatistics and Clinical Research University of Muenster Muenster Germany
IWK Health Center Dalhousie University Halifax NS Canada
Keck School of Medicine University of Southern California Los Angeles CA USA
Klinik für Allgemeine Orthopädie und Tumororthopädie University of Muenster Muenster Germany
Klinikum Stuttgart Olgahospital Cooperative Osteosarcoma Study Group Stuttgart Germany
Leiden University Medical Center Leiden Netherlands
Medical Research Council Clinical Trials Unit at University College London London UK
National Medical Center Oncology Department Budapest Hungary
Newcastle upon Tyne Hospitals NHS Trust Newcastle upon Tyne UK
Pädiatrische Hämatologie und Onkologie Universitätsklinikum Bonn Bonn Germany
Pädiatrische Hämatologie und Onkologie University of Muenster Muenster Germany
Primary Childrens Hospital The University of Utah Salt Lake City UT USA
Royal Manchester Children's Hospital Manchester UK
Skane University Hospital and Lund University Lund Sweden
St James' Institute of Oncology Leeds UK
Stanford University School of Medicine and Lucile Packard Children's Hospital Palo Alto CA USA
Texas Children's Cancer Center Baylor College of Medicine Houston TX USA
UCSF Medical Center Mission Bay Pediatric Oncology San Francisco CA USA
University Children's Hospital Basel Basel Switzerland
University Hospital Motol Pediatric Hematology Oncology Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023747
- 003
- CZ-PrNML
- 005
- 20170720123550.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(16)30214-5 $2 doi
- 035 __
- $a (PubMed)27569442
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Marina, Neyssa M $u Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA, USA.
- 245 10
- $a Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial / $c NM. Marina, S. Smeland, SS. Bielack, M. Bernstein, G. Jovic, MD. Krailo, JM. Hook, C. Arndt, H. van den Berg, B. Brennan, B. Brichard, KL. Brown, T. Butterfass-Bahloul, G. Calaminus, HE. Daldrup-Link, M. Eriksson, MC. Gebhardt, H. Gelderblom, J. Gerss, R. Goldsby, A. Goorin, R. Gorlick, HE. Grier, JP. Hale, KS. Hall, J. Hardes, DS. Hawkins, K. Helmke, PC. Hogendoorn, MS. Isakoff, KA. Janeway, H. Jürgens, L. Kager, T. Kühne, CC. Lau, PJ. Leavey, SL. Lessnick, L. Mascarenhas, PA. Meyers, H. Mottl, M. Nathrath, Z. Papai, RL. Randall, P. Reichardt, M. Renard, AA. Safwat, CL. Schwartz, MC. Stevens, SJ. Strauss, L. Teot, M. Werner, MR. Sydes, JS. Whelan,
- 520 9_
- $a BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m(2), doxorubicin 37·5 mg/m(2) per day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m(2) over 4 h. The MAPIE regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m(2)) at 2·8 g/m(2) per day with equidose mesna uroprotection, followed by etoposide 100 mg/m(2) per day over 1 h on days 1-5. The primary outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00134030. FINDINGS: Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6-76·6); 62·3 months (IQR 46·9-77·1) for the MAP group and 61·1 months (IQR 46·5-75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0·98 [95% CI 0·78-1·23]); hazards were non-proportional (p=0·0003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically doxorubicin and cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically doxorubicin). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to methotrexate. INTERPRETATION: EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival. The results define standard of care for this population. New strategies are required to improve outcomes in this setting. FUNDING: UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a nádory kostí $x farmakoterapie $x mortalita $7 D001859
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a osteosarkom $x farmakoterapie $x mortalita $7 D012516
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Smeland, Sigbjørn $u Oslo University Hospital, Division of Cancer Medicine and Scandinavian Sarcoma Group, University of Oslo, Norway; Institute for Clinical Medicine, University of Oslo, Norway.
- 700 1_
- $a Bielack, Stefan S $u Klinikum Stuttgart-Olgahospital, Cooperative Osteosarcoma Study Group (COSS), Stuttgart, Germany.
- 700 1_
- $a Bernstein, Mark $u IWK Health Center, Dalhousie University, Halifax, NS, Canada.
- 700 1_
- $a Jovic, Gordana $u Medical Research Council Clinical Trials Unit at University College London, London, UK.
- 700 1_
- $a Krailo, Mark D $u Department of Preventive Medicine, Keck Medical Canter at the University of Southern California, Los Angeles CA, USA; Children's Oncology Group, Arcadia, CA, USA.
- 700 1_
- $a Hook, Jane M $u Medical Research Council Clinical Trials Unit at University College London, London, UK; Clinical Trials Research Unit, Institute of Clinical Trials Research, University of Leeds, Leeds, UK; St James' Institute of Oncology, Leeds, UK.
- 700 1_
- $a Arndt, Carola $u Division of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. $7 gn_A_00008659
- 700 1_
- $a van den Berg, Henk $u Emma Children Hospital/Academic Medical Centre, Amsterdam, Netherlands.
- 700 1_
- $a Brennan, Bernadette $u Royal Manchester Children's Hospital, Manchester, UK.
- 700 1_
- $a Brichard, Bénédicte $u Department of Pediatric Hematology/Oncology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
- 700 1_
- $a Brown, Ken L B $u Department of Orthopaedics, University of British Columbia, Vancouver, BC, Canada.
- 700 1_
- $a Butterfass-Bahloul, Trude $u Centre for Clinical Trials, University Hospital Muenster, Muenster, Germany.
- 700 1_
- $a Calaminus, Gabriele $u Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Bonn, Bonn, Germany.
- 700 1_
- $a Daldrup-Link, Heike E $u Department of Radiology, Stanford University and Lucile Packard Children's Hospital, Palo Alto, CA, USA.
- 700 1_
- $a Eriksson, Mikael $u Skane University Hospital and Lund University, Lund, Sweden.
- 700 1_
- $a Gebhardt, Mark C $u Department of Surgery, Dana-Farber Cancer Institute, Boston, MA, USA.
- 700 1_
- $a Gelderblom, Hans $u Leiden University Medical Center, Leiden, Netherlands.
- 700 1_
- $a Gerss, Joachim $u Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
- 700 1_
- $a Goldsby, Robert $u UCSF Medical Center-Mission Bay, Pediatric Oncology, San Francisco, CA, USA.
- 700 1_
- $a Goorin, Allen $u Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute, Boston, MA, USA.
- 700 1_
- $a Gorlick, Richard $u Division of Pediatric Hematology-Oncology, The Children's Hospital at Montefiore, Bronx, NY, USA.
- 700 1_
- $a Grier, Holcombe E $u Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute, Boston, MA, USA.
- 700 1_
- $a Hale, Juliet P $u Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
- 700 1_
- $a Hall, Kirsten Sundby $u Department of Oncology, Oslo University Hospital, Norwegian Radium Hospital, Scandinavian Sarcoma Group, Oslo, Norway.
- 700 1_
- $a Hardes, Jendrik $u Klinik für Allgemeine Orthopädie und Tumororthopädie, University of Muenster, Muenster, Germany.
- 700 1_
- $a Hawkins, Douglas S $u Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
- 700 1_
- $a Helmke, Knut $u Abt Pädiatrische Radiologie, AKK Altonaer Kinderkrankenhaus, Hamburg, Germany.
- 700 1_
- $a Hogendoorn, Pancras C W $u Leiden University Medical Center, Leiden, Netherlands.
- 700 1_
- $a Isakoff, Michael S $u Center for Cancer and Blood Disorders, Connecticut Children's Medical Center, Hartford, CT, USA.
- 700 1_
- $a Janeway, Katherine A $u Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute, Boston, MA, USA.
- 700 1_
- $a Jürgens, Heribert $u Pädiatrische Hämatologie und Onkologie, University of Muenster, Muenster, Germany.
- 700 1_
- $a Kager, Leo $u Department of Pediatrics, St Anna Children's Hospital, Medical University Vienna, Vienna, Austria.
- 700 1_
- $a Kühne, Thomas $u University Children's Hospital Basel, Basel, Switzerland.
- 700 1_
- $a Lau, Ching C $u Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.
- 700 1_
- $a Leavey, Patrick J $u Department of Pediatrics, UT Southwestern and Children's Medical Center, Dallas, TX, USA.
- 700 1_
- $a Lessnick, Stephen L $u Center for Childhood Cancer and Blood Disorders, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, USA.
- 700 1_
- $a Mascarenhas, Leo $u Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
- 700 1_
- $a Meyers, Paul A $u Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- 700 1_
- $a Mottl, Hubert $u University Hospital Motol, Pediatric Hematology/Oncology, Prague, Czech Republic.
- 700 1_
- $a Nathrath, Michaela $u Clinical Cooperation Group Osteosarcoma, Pediatric Oncology Center, Department of Pediatrics, Technical University Munich, Munich, Germany; Department of Pediatric Oncology, Klinikum Kassel, Kassel, Germany.
- 700 1_
- $a Papai, Zsuzsanna $u National Medical Center, Oncology Department, Budapest, Hungary.
- 700 1_
- $a Randall, R Lor $u Primary Childrens Hospital, The University of Utah, Salt Lake City, UT, USA.
- 700 1_
- $a Reichardt, Peter $u HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie, Berlin, Germany.
- 700 1_
- $a Renard, Marleen $u Department of Pediatric Hemato-oncology, University Hospital Leuven, Leuven, Belgium.
- 700 1_
- $a Safwat, Akmal Ahmed $u Aarhus University Hospital, Aarhus C, Denmark.
- 700 1_
- $a Schwartz, Cindy L $u Division of Pediatrics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
- 700 1_
- $a Stevens, Michael C G $u Bristol Royal Hospital for Children, Bristol, UK.
- 700 1_
- $a Strauss, Sandra J $u Department of Oncology, University College Hospital, London, UK.
- 700 1_
- $a Teot, Lisa $u Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
- 700 1_
- $a Werner, Mathias $u HELIOS Klinikum Emil von Behring GmbH, Orthopädische Pathologie, Berlin, Germany.
- 700 1_
- $a Sydes, Matthew R $u Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: mrcctu.euramos@ucl.ac.uk.
- 700 1_
- $a Whelan, Jeremy S $u Department of Oncology, University College Hospital, London, UK.
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 17, č. 10 (2016), s. 1396-1408
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27569442 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170720124043 $b ABA008
- 999 __
- $a ok $b bmc $g 1239428 $s 984660
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 17 $c 10 $d 1396-1408 $e 20160825 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20170720
